CSL (ASX:CSL) Institutional Ownership : 34.41% (As of May. 01, 2024)

View and export this data going back to 1994. Start your Free Trial

What is CSL Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CSL's institutional ownership is 34.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CSL's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CSL's Float Percentage Of Total Shares Outstanding is 0.00%.

CSL Institutional Ownership Historical Data

The historical data trend for CSL's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Institutional Ownership Chart

CSL Historical Data

The historical data trend for CSL can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	35.10	34.93	35.12	33.88	33.89	34.11	34.76	34.81	34.67	34.41

CSL Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

CSL (ASX:CSL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CMXHF:USA CSJ:Germany

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.